Kymera Therapeutics Income Statement (2019-2026) | KYMR

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
18.52M20.34M15.28M9.62M11.51M9.55M16.14M9.47M16.51M4.73M47.88M10.29M25.65M3.74M7.39M22.10M11.48M2.76M2.87M34.37M
Operating items
Research & Development (Quarter)
35.22M38.31M37.53M35.94M41.29M43.88M43.13M42.23M45.77M48.12M52.97M48.82M59.20M60.41M71.82M80.25M78.39M74.09M83.83M98.16M
Selling, General & Administrative (Quarter)
8.03M10.67M11.74M10.61M11.03M10.56M11.64M12.56M14.13M14.12M14.23M14.37M17.37M15.46M16.33M16.27M17.64M17.34M16.93M20.36M
Other Operating Expenses (Quarter)
4.92M3.85M
Operating Expenses (Quarter)
43.25M48.97M49.27M46.55M52.32M54.43M54.77M54.79M59.90M62.24M67.20M68.12M76.58M75.86M88.15M96.53M96.03M95.28M100.77M118.52M
Operating Income (Quarter)
-24.73M-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M-97.90M-84.15M
EBIT (Quarter)
-24.73M-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M-97.90M-84.15M
Non-operating items
Other Non Operating Income (Quarter)
0.07M0.06M0.27M0.29M0.55M1.92M3.82M4.40M4.63M4.68M4.80M9.27M8.86M9.70M9.81M8.85M7.94M10.44M11.01M14.92M
Non Operating Income (Quarter)
0.07M0.06M0.09M0.25M0.55M1.88M3.77M4.40M4.58M4.64M4.94M9.27M8.86M9.64M10.00M8.85M7.94M10.35M10.91M14.92M
Net income details
EBT (Quarter)
-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M-97.99M-84.22M
Profit After Tax (Quarter)
-24.66M-28.58M-33.90M-36.68M-40.26M-43.00M-34.87M-40.93M-38.80M-52.87M-14.37M-48.56M-42.06M-62.49M-70.75M-65.58M-76.61M-82.17M-86.98M-69.23M
Income from Continuing Operations (Quarter)
-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M-97.99M-84.22M
Consolidated Net Income (Quarter)
-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M-97.99M-84.22M
Income towards Parent Company (Quarter)
-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M-97.99M-84.22M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-24.66M-28.71M-34.05M-36.97M-40.26M-43.00M-34.87M-40.93M-38.80M-52.87M-14.37M-48.56M-42.06M-62.49M-70.75M-65.58M-76.61M-82.17M-86.98M-69.23M
Additional items
EPS (Basic) (Quarter)
-0.55-0.56-0.67-0.71-0.78-0.79-0.59-0.70-0.67-0.90-0.25-0.69-0.58-0.82-0.89-0.82-0.95-0.94-0.98-0.71
EPS (Weighted Average and Diluted) (Quarter)
-0.55-0.56-0.67-0.71-0.78-0.79-0.59-0.70-0.67-0.90-0.25-0.69-0.58-0.82-0.89-0.82-0.95-0.94-0.98-0.71
Shares Outstanding (Weighted Average) (Quarter)
44.87M50.71M47.99M51.65M51.71M54.54M53.93M58.19M58.33M58.31M58.37M70.77M73.06M73.33M75.04M80.15M80.45M82.65M84.49M97.53M
Shares Outstanding (Diluted Average) (Quarter)
45.09M46.84M47.99M51.65M51.77M52.60M53.93M58.19M58.26M58.31M58.37M70.77M73.06M76.13M75.04M80.15M80.30M87.30M84.49M97.53M
EBITDA (Quarter)
-24.65M-28.73M-34.41M-39.24M-41.02M-44.93M-33.90M-39.02M-39.40M-51.68M-12.47M-49.78M-42.38M-58.46M-74.17M-64.15M-76.28M-80.95M-86.68M-75.23M
Interest Expenses (Quarter)
0.03M0.07M0.05M0.04M0.04M0.04M0.06M0.06M0.05M0.04M0.05M0.07M0.06M0.06M0.06M0.07M0.11M0.10M0.09M0.06M